

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 October 2023 (19.10.2023)



(10) International Publication Number
WO 2023/201043 A1

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 47/54 (2017.01)
A61K 31/713 (2006.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2023/018657

(22) International Filing Date:

14 April 2023 (14.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/363,091 15 April 2022 (15.04.2022) US

(71) Applicant: **DICERNA PHARMACEUTICALS, INC.**
[US/US]; 75 Hayden Avenue, Lexington, Massachusetts
02421 (US).

(72) Inventors: **BROWN, Bob Dale**; c/o Dicerna Pharmaceu-
ticals, Inc., 75 Hayden Avenue, Lexington, Massachusetts
02421 (US). **DUDEK, Henryk T.**; c/o Dicerna Pharmaceu-
ticals, Inc., 75 Hayden Avenue, Lexington, Massachusetts
02421 (US). **CHEONG, Seongmoon**; c/o Dicerna Phar-
maceuticals, Inc., 75 Hayden Avenue, Lexington, Massa-
chusetts 02421 (US). **SPIEGELMAN, Nicole Alexis**; c/o
Dicerna Pharmaceuticals, Inc., 75 Hayden Avenue, Lexing-
ton, Massachusetts 02421 (US).

(74) Agent: **REID, Andrea L.C.** et al.; c/o Dechert LLP, One
International Place, 40th Floor, 100 Oliver Street, Boston,
Massachusetts 02110-2605 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

WO 2023/201043 A1

(54) Title: COMPOSITIONS AND METHODS FOR MODULATING SCAP ACTIVITY

(57) Abstract: Oligonucleotides and compositions including the same are disclosed that modulate (e.g., inhibit, limit or reduce) sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP) activity. Methods of making and using the oligonucleotides also are disclosed, particularly uses relating to treating diseases, disorders, and/or conditions associated with SCAP activity such as nonalcoholic fatty liver disease (NAFLD), (NASH), dyslipidemia, atherosclerotic cardiovascular disease (ASCVD), and/or other SCAP-associated conditions, diseases, and/or disorders.